keyword
MENU ▼
Read by QxMD icon Read
search

Vasculitis ANCA

keyword
https://www.readbyqxmd.com/read/29780146/propylthiouracil-induced-otitis-media-with-antineutrophil-cytoplasmic-antibody-associated-vasculitis
#1
Rika Tanaka, Yasuhiro Shimojima, Hideaki Moteki, Dai Kishida, Ken-Ichi Ueno, Yoshiki Sekijima
We herein report a case of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) induced by propylthiouracil (PTU). A 30-year-old Japanese woman with Graves' disease, who was treated with PTU, reported with otitis media with sensorineural hearing loss bilaterally and trigeminal neuralgia on the left side, as well as elevated serum levels of myeloperoxidase-ANCA. Prior treatment with antibiotics was ineffective even after tympanostomy. However, clinical remission was immediately achieved after initiating prednisolone together with PTU withdrawal...
May 18, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29769093/granulomatosis-with-polyangiitis-a-17-year-experience-from-a-tertiary-care-hospital-in-pakistan
#2
Omar Irfan, Haris Khan, Zarrar Khan, Alina Ashraf, Rimsha Ahmed, Javaid Ahmad Khan, Ali Bin Sarwar Zubairi
OBJECTIVE: Granulomatosis with Polyangiitis (GPA) is an autoimmune, multi-system, small and medium vessel vasculitis with granulomatous inflammation. Aim of this study was to assess the clinical and radiological presentations of patients with GPA amongst the Pakistani population. It is a single centre retrospective single observation study. RESULTS: Study was conducted at the Aga Khan University Hospital, Karachi with records were reviewed from January 2000 to December 2017...
May 16, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29768245/exploring-the-potential-of-mucin-13-muc13-as-a-biomarker-for-carcinomas-and-other-diseases
#3
Panagiota S Filippou, Annie H Ren, Dimitrios Korbakis, Lampros Dimitrakopoulos, Antoninus Soosaipillai, Vivian Barak, Shahar Frenkel, Jacob Pe'er, Michal Lotem, Sharon Merims, Rafael Molina, Ivan Blasutig, Dimitrios P Bogdanos, Eleftherios P Diamandis
BACKGROUND: Mucin 13 (MUC13) is a cell surface glycoprotein aberrantly expressed in a variety of epithelial carcinomas. Thus far, the role of MUC13 in various diseases remains elusive. To the best of our knowledge, this is the first study to examine the potential of MUC13 as a serum biomarker in a variety of carcinomas and other conditions. METHODS: We developed a recombinant MUC13 protein, mouse monoclonal antibodies and enzyme immunoassay (ELISA) for MUC13. We used this assay to measure MUC13 levels in the supernatants of cancer cell lines and a large cohort of serum samples from healthy and diseased individuals...
May 16, 2018: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/29765786/nasal-septal-perforation-in-propylthiouracil-induced-anti-neutrophil-cytoplasmic-antibody-associated-vasculitis
#4
Yusho Ishii, Tsuyoshi Shirai, Yousuke Hoshi, Yoko Fujita, Yuko Shirota, Hiroshi Fujii, Tomonori Ishii, Hideo Harigae
Here, we present the case of a 29-year-old woman with nasal septal perforation and positive myeloperoxidase- (MPO-) anti-neutrophil cytoplasmic antibody (ANCA). She had been diagnosed with Graves' disease and had been treated with propylthiouracil (PTU) for 14 months. A biopsy of the nasal septum revealed an infiltration of inflammatory cells, with no evidence of malignancy or granulomatous change. Because of the use of PTU, destructive nasal lesion, and positive MPO-ANCA, she was diagnosed with drug-induced ANCA-associated vasculitis (AAV) and was treated with prednisolone and methotrexate after the cessation of PTU...
2018: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/29763902/prognostic-factors-of-renal-involvement-in-systemic-sclerosis
#5
Edoardo Rosato, Antonietta Gigante, Biagio Barbano, Maria Ludovica Gasperini, Rosario Cianci, Maurizio Muscaritoli
BACKGROUND/AIMS: Renal involvement is common in systemic sclerosis (SSc), including asymptomatic reduction of glomerular filtration rate (GFR), increased renal resistance indices, scleroderma renal crisis (SRC) and ANCA-associated vasculitis. The aim was to evaluate type and evolution of renal involvement for a period of five years. METHODS: 121 SSc patients (100 F, 21 M) with mean age of 54.9 ± 13.8, disease duration of 9 ± 6 years, of which 62 had a diffused form and 59 limited form were enrolled...
May 10, 2018: Kidney & Blood Pressure Research
https://www.readbyqxmd.com/read/29760925/methimazole-induced-anca-associated-vasculitis-with-diffuse-alveolar-haemorrhage
#6
Naoki Arai, Kenji Nemoto, Shuji Oh-Ishi, Mizu Nonaka, Kenji Hayashihara, Takefumi Saito
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) caused by methimazole (MMI) is known to be relatively rare; therefore, the optimal therapeutic approach for these cases remains to be established. A 59-year-old man who was treated with MMI for a diagnosis of Graves' disease was referred to our hospital because of progressive haemoptysis. The patient was diagnosed with diffuse alveolar haemorrhage (DAH) secondary to AAV based on increased inflammatory reactions with positive myeloperoxidase-ANCA in the serum and the results of bronchoalveolar lavage fluid...
July 2018: Respirology Case Reports
https://www.readbyqxmd.com/read/29755460/proteinase-3-interferes-with-c1q-mediated-clearance-of-apoptotic-cells
#7
Pascale Tacnet-Delorme, Julie Gabillet, Simon Chatfield, Nathalie Thieblemont, Philippe Frachet, Véronique Witko-Sarsat
Proteinase 3 (PR3) is the autoantigen in granulomatosis with polyangiitis, an autoimmune necrotizing vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCAs). Moreover, PR3 is a serine protease whose membrane expression can potentiate inflammatory diseases such as ANCA-associated vasculitis and rheumatoid arthritis. During apoptosis, PR3 is co-externalized with phosphatidylserine (PS) and is known to modulate the clearance of apoptotic cells through a calreticulin (CRT)-dependent mechanism...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29745882/the-adenosinergic-system-a-potential-player-in-the-pathogenesis-of-anca-associated-vasculitis
#8
REVIEW
Lovis Kling, Bernhard K Krämer, Benito A Yard, Anna-Isabelle Kälsch
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a potentially lethal autoimmune disease whose pathology comprises disturbed T cell differentiation and functionality accompanied by dysfunctional autoreactive immunoglobulin development, culminating in destructive innate immune response as well. Purines, adenine nucleotides and adenosine in particular, have been elucidated as potent extracellular mediators for fine adjustment of these pivotal processes establishing human immunity. Therefore, the extracellular purinergic microenvironment is under control of ectonucleotidases CD39 and CD73 degrading pro-inflammatory adenosine triphosphate (ATP) to anti-inflammatory adenosine as well as adenosine deaminase bound to CD26 deactivating adenosine...
May 3, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29740582/anti-high-density-lipoprotein-antibodies-and-antioxidant-dysfunction-in-immune-driven-diseases
#9
Javier Rodríguez-Carrio, Lourdes Mozo, Patricia López, Elena Nikiphorou, Ana Suárez
Introduction: Impaired high-density lipoprotein (HDL) levels and antioxidant functionality of HDL, mainly attributed to a decreased paraoxonase-1 (PON1) functionality, have been described in autoimmune conditions. In this setting, a role for humoral response in cardiovascular disease is emerging. This study evaluates the role of immunoglobulin G (IgG) antibodies against HDL and disease-related autoantibodies on HDL dysfunction in immune-driven diseases. Methods: Serum IgG anti-HDL antibodies, PON1 activity, and total antioxidant capacity (TAC) were quantified in 381 patients with different immune-driven diseases [18 mixed connective tissue disease (MCTD), 35 primary Sjögren syndrome (pSS), 38 systemic sclerosis (SSc), 33 ANCA-associated vasculitis (AAV), 60 diabetes mellitus 1, 29 autoimmune B12 deficiency/pernicious anemia, 29 primary biliary cirrhosis, 46 IBD/Crohn, 54 IBD/UC, and 39 celiac disease (CD)] and 138 healthy controls...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29738027/hydralazine-associated-adverse-events-a-report-of-two-cases-of-hydralazine-induced-anca-vasculitis
#10
Roman Zuckerman, Mayurkumar Patel, Eric J Costanzo, Harry Dounis, Rany Al Haj, Seyedehsara Seyedali, Arif Asif
Hydralazine is a direct-acting vasodilator, which has been used in treatment for hypertension (HTN) since the 1950s. While it is well known to cause drug-induced lupus (DIL), recent reports are indicating the emergence of the drug-induced anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (DIV). Herein, we describe two patients (aged 57 and 87 years) who presented with severe acute kidney injury (AKI), proteinuria, and hematuria. Both were receiving hydralazine for the treatment of hypertension...
May 7, 2018: Jornal Brasileiro de Nefrologia: ʹorgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia
https://www.readbyqxmd.com/read/29729450/new-use-for-an-old-treatment-hydroxychloroquine-as-a-potential-treatment-for-systemic-vasculitis
#11
REVIEW
Alina Casian, Shirish Sangle, David P D'Cruz
Antimalarials have been an effective and safe treatment for autoimmune rheumatic diseases such as systemic lupus erythematosus for more than a hundred years. There are surprisingly few reports of hydroxychloroquine use in the systemic vasculitides. Hydroxychloroquine has antithrombotic, cardiovascular, antimicrobial and antineoplastic effects, making it a potentially valuable treatment for patients with systemic vasculitis who are at risk of infections, malignancy and thrombotic events. We report the successful use of hydroxychloroquine in patients with ANCA vasculitis, Henoch Schonlein purpura/IgA vasculitis, Takayasu's arteritis and polyarteritis nodosa...
May 2, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29725643/combination-therapy-with-rituximab-and-cyclophosphamide-for-remission-induction-in-anca-vasculitis
#12
Frank B Cortazar, Saif A Muhsin, William F Pendergraft, Zachary S Wallace, Colleen Dunbar, Karen Laliberte, John L Niles
Introduction: Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab with a short course of low-dose, oral cyclophosphamide and an accelerated prednisone taper. Methods: Patients were included in this retrospective study if they had newly diagnosed or relapsing ANCA vasculitis with a Birmingham Vasculitis Activity Score for Wegener Granulomatosis (BVAS-WG) ≥3 and received a standardized remission induction regimen...
March 2018: KI Reports
https://www.readbyqxmd.com/read/29724729/long-term-efficacy-of-remission-maintenance-regimens-for-anca-associated-vasculitides
#13
Benjamin Terrier, Christian Pagnoux, Élodie Perrodeau, Adexandre Karras, Chahera Khouatra, Olivier Aumaître, Pascal Cohen, Olivier Decaux, Hélène Desmurs-Clavel, François Maurier, Pierre Gobert, Thomas Quémeneur, Claire Blanchard-Delaunay, Bernard Bonnotte, Pierre-Louis Carron, Eric Daugas, Marize Ducret, Pascal Godmer, Mohamed Hamidou, Olivier Lidove, Nicolas Limal, Xavier Puéchal, Luc Mouthon, Philippe Ravaud, Loïc Guillevin
OBJECTIVE: To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. METHODS: The 28-month Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis trial compared rituximab with azathioprine to maintain remission in patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis or renal-limited ANCA-associated vasculitis...
May 3, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29721696/pyoderma-gangrenosum-like-ulcerations-in-granulomatosis-with-polyangiitis-two-cases-and-literature-review
#14
REVIEW
Giovanni Genovese, Simona Tavecchio, Emilio Berti, Franco Rongioletti, Angelo Valerio Marzano
Granulomatosis with polyangiitis (GPA) is a systemic necrotizing small vessel vasculitis associated with circulating anti-neutrophil cytoplasmic antibodies (ANCAs). Skin manifestations, mostly represented by palpable purpura, papulonodular lesions and livedo reticularis, are present in up to 50% of the cases. Ulcerations with undermined, raised erythematous-violaceous border resembling pyoderma gangrenosum (PG) have rarely been reported as skin involvement in GPA. The presence of circulating ANCAs with a cytoplasmic labelling pattern, the involvement of internal organs, particularly of the lung, and the absence on histology of a mainly neutrophilic infiltrate in early phases of the cutaneous lesions may be regarded as clues to rule out true PG and confirm the diagnosis of GPA skin ulcerations simulating PG...
May 2, 2018: Rheumatology International
https://www.readbyqxmd.com/read/29720895/monocyte-chemoattractant-protein-1-in-antineutrophil-cytoplasmic-autoantibody-associated-vasculitis-biomarker-potential-and-association-with-polymorphisms-in-the-mcp-1-and-the-cc-chemokine-receptor-2-gene
#15
Nina Jönsson, Evelina Erlandsson, Lena Gunnarsson, Åsa Pettersson, Sophie Ohlsson
Antineutrophil cytoplasmic autoantibody- (ANCA-) associated vasculitis (AAV) are relapsing-remitting disorders with unpredictable prognosis. There is a need of biomarkers for distinguishing which patients will have a more severe outcome and also for predicting relapses in disease activity. This study confirms the previous results of urinary MCP-1 (uMCP-1) as a prognostic marker and explores its potential as a marker of disease activity. Method . 114 patients with AAV were followed regularly between 2002 and 2011 at Skåne University Hospital...
2018: Mediators of Inflammation
https://www.readbyqxmd.com/read/29718732/avacopan-in-the-treatment-of-anca-associated-vasculitis
#16
Vladimir Tesar, Zdenka Hruskova
ANCA-associated vasculitis (AAV) is a rare but potentially life-threatening disease. Currently used induction treatment (cyclophosphamide or rituximab with high-dose corticosteroids) has significantly improved outcome of AAV, but is associated with high toxicity. Alternative complement pathway activation was shown to play a role in the pathogenesis of AAV, thus providing rationale for the use of avacopan, a selective inhibitor of C5a receptor, in the treatment of AAV. Areas Covered: Pharmacokinetic and pharmocodynamic properties of avacopan, clinical efficacy and safety and tolerability of avacopan in so far performed clinical trials in patients with AAV are reviewed and discussed...
May 2, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29709950/an-autopsy-case-of-myeloperoxidase-anti-neutrophil-cytoplasmic-antibody-mpo-anca-associated-vasculitis-accompanied-by-cryoglobulinemic-vasculitis-affecting-the-kidneys-skin-and-gastrointestinal-tract
#17
Jumpei Hasegawa, Sachiko Wakai, Momoko Kono, Yusuke Imaizumi, Sakiko Masuda, Akihiro Ishizu, Kazuho Honda
Anti-neutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV) and cryoglobulinemic vasculitis (CV) rarely coexist. An 83-year-old woman was admitted with rapidly progressive renal failure, gastrointestinal hemorrhage and purpura with myeloperoxidase (MPO) -ANCA positivity and cryoglobulinemia. Despite intensive immunosuppressive treatment, she died of aspergillus pneumonia. Autopsy revealed necrotizing crescentic glomerulitis in the majority of the glomeruli, accompanied by partially membranoproliferative-like glomerular changes...
April 27, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29695500/comparison-of-individually-tailored-versus-fixed-schedule-rituximab-regimen-to-maintain-anca-associated-vasculitis-remission-results-of-a-multicentre-randomised-controlled-phase-iii-trial-mainritsan2
#18
Pierre Charles, Benjamin Terrier, Élodie Perrodeau, Pascal Cohen, Stanislas Faguer, Antoine Huart, Mohamed Hamidou, Christian Agard, Bernard Bonnotte, Maxime Samson, Alexandre Karras, Noémie Jourde-Chiche, François Lifermann, Pierre Gobert, Catherine Hanrotel-Saliou, Pascal Godmer, Nicolas Martin-Silva, Grégory Pugnet, Marie Matignon, Olivier Aumaitre, Jean-François Viallard, François Maurier, Nadine Meaux-Ruault, Sophie Rivière, Jean Sibilia, Xavier Puéchal, Philippe Ravaud, Luc Mouthon, Loïc Guillevin
OBJECTIVE: To compare individually tailored, based on trimestrial biological parameter monitoring, to fixed-schedule rituximab reinfusion for remission maintenance of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs). METHODS: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in complete remission after induction therapy were included in an open-label, multicentre, randomised controlled trial...
April 25, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29695498/validation-of-the-anca-associated-vasculitis-patient-reported-outcomes-aav-pro-questionnaire
#19
Joanna Robson, Jill Dawson, Helen Doll, Peter F Cronholm, Nataliya Milman, Katherine Kellom, Susan Ashdown, Ebony Easley, Don Gebhart, Georgia Lanier, John Mills, Jacqueline Peck, Raashid Ahmed Luqmani, Judy Shea, Gunnar Tomasson, Peter Merkel
ObjectivesTo finalise and validate a disease-specific patient-reported outcome (PRO) measure: the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire. Using a 35-item candidate questionnaire developed following 50 qualitative interviews in the UK, USA and Canada, a longitudinal survey was conducted to determine the final scale structure and validate the AAV-PRO. METHODS: Participants were recruited via Vasculitis UK and the Vasculitis Patient-Powered Research Network...
April 25, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29693324/circulating-cytokine-profiles-and-anca-specificity-in-patients-with-anca-associated-vasculitis
#20
Alvise Berti, Roscoe Warner, Kent Johnson, Divi Cornec, Darrell Schroeder, Brian Kabat, Carol A Langford, Gary S Hoffman, Fernanado C Fervenza, Cees G M Kallenberg, Philip Seo, Robert Spiera, E William St Clair, Paul Brunetta, John H Stone, Peter A Merkel, Ulrich Specks, Paul A Monach
OBJECTIVES: To evaluate circulating cytokine profiles in patients with ANCA-associated vasculitis (AAV), classified by ANCA specificity (proteinase 3 (PR3)-ANCA versus myeloperoxidase (MPO)-ANCA) or by clinical diagnosis (granulomatosis with polyangiitis (GPA) versus microscopic polyangiitis (MPA)). METHODS: A panel of 29 cytokines was tested in 186 patients with active AAV at inclusion into the Rituximab in AAV (RAVE) trial. Cytokine concentrations were compared between groups within each classification system...
April 25, 2018: Arthritis & Rheumatology
keyword
keyword
96320
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"